Claims
- 1. A method for treating cardiac disease, comprising the step of administering to a patient in need of treatment an effective amount of a compound having the following general formula (II) or pharmacologically acceptable salts thereofChemical formula 2 wherein R51 represents hydrogen atom, an alkyl group having 1-8 carbon atoms, a haloalkyl group having 1-8 carbon atoms, or —NR57R58; R52 represents —C(═O)— or single bond; R53 represents —OR59, a 3-7 membered saturated aliphatic cyclic amino group optionally interrupted with nitrogen atom, oxygen atom or sulfur atom, a 3-7 membered saturated aliphatic cyclic amino group containing at least one nitrogen atom and substituted with an alkyl group having 1-8 carbon atoms or a haloalkyl group having 1-8 carbon atoms in the ring, or —NR60R61; R54 represents hydrogen atom, an alkyl group having 1-8 carbon atoms, a haloalkyl group having 1-8 carbon atoms, —(CH2)mNR62R63, —(CH2)nR64, —(CH2)pCH(NR65R66)COOR67, —R68—COOR69, —CH(R70)OC(═O)OR71, or —CH(R72)OC(═O)R73; R60 and R61 each independently represents hydrogen atom, an alkyl group having 1-8 carbon atoms, a haloalkyl group having 1-8 carbon atoms, or —(CH2)qNR74R75; R64 represents a 3-7 membered saturated aliphatic cyclic amino group optionally interrupted with nitrogen atom, oxygen atom or sulfur atom, a 3-7 membered saturated aliphatic cyclic amino group containing at least one nitrogen atom and substituted with an alkyl group having 1-8 carbon atoms or a haloalkyl group having 1-8 carbon atoms in the ring, a 3-7 membered saturated aliphatic cyclic alkyl group containing at least one nitrogen atom and substituted with an alkyl group having 1-8 carbon atoms or a haloalkyl group having 1-8 carbon atoms in the ring, or a 3-7 membered unsaturated heterocyclic group; R68 represents a 3-7 membered saturated aliphatic cyclic alkylene group containing at least one nitrogen atom and substituted with a alkyl group having 1-8 carbon atoms or a haloalkyl group having 1-8 carbon atoms in the ring; R71 and R73 represent —(CH2)rR76; R76 represents hydrogen atom, an alkyl group having 1-8 carbon atoms, a haloalkyl group having 1-8 carbon atoms, —NR77R78, or a 3-8 membered saturated aliphatic cyclic alkyl group; Z represents C[, CH, or N]; A represents CH or N; R55, R56, R57,R58,R59,R62,R63,R65, R66, R67, R69, R70, R72,R74, R75, R77 and R78 each independently represents hydrogen atom, an alkyl group having 1-8 carbon atoms, or a haloalkyl group having 1-8 carbon atoms; m, q and r each independently represents an integer of 1-6; n and p each independently represents 0 or an integer of 1-6, with a proviso when R54 represents hydrogen atom, an alkyl group having 1-8 carbon atoms, or a haloalkyl group having 1-8 carbon atoms, then R53 represents a 3-7 membered saturated aliphatic cyclic amino group containing at least one nitrogen atom and substituted with an alkyl group having 1-8 carbon atoms or a haloalkyl group having 1-8 carbon atoms in the ring, a 3-7 membered saturated aliphatic cyclic alkyl group containing at least one nitrogen atom and substituted with an alkyl group having 1-8 carbon atoms or a haloalkyl group having 1-8 carbon atoms in the ring, or —NR60R61 wherein at least one of R60 and R61 represent —(CH2)qNR74R75.
- 2. The method according to claim 1, wherein R51 represents an alkyl group having 1-8 carbon atoms, a haloalkyl group having 1-8 carbon atoms; R52 represents —C(═O)—; R53 represents—OR59, a 3-7 membered saturated aliphatic cyclic amino group optionally interrupted with nitrogen atom, oxygen atom or sulfur atom, a 3-7 membered saturated aliphatic cyclic amino group containing at least one nitrogen atom and substituted with an alkyl group having 1-8 carbon atoms or a haloalkyl group having 1-8 carbon atoms in the ring, or —NR60R61; R54 represents —(CH2)mNR62R63, —(CH2)nR64, —(CH2)pCH(NR65R66)COOR67, —R68—COOR69, —CH(R70)OC(═O)OR71, or —CH(R72)OC(═O)R73; R60 and R61 each independently represents hydrogen atom, an alkyl group having 1-8 carbon atoms, a haloalkyl group having 1-8 carbon atoms, or —(CH2)qNR74R75; R64 represents a 3-7 membered saturated aliphatic cyclic amino group optionally interrupted with nitrogen atom, oxygen atom or sulfur atom, a 3-7 membered saturated aliphatic cyclic amino group containing at least one nitrogen atom and substituted with an alkyl group having 1-8 carbon atoms or a haloalkyl group having 1-8 carbon atoms in the ring, or a 3-7 membered unsaturated heterocyclic group; R68 represents a 3-7 membered saturated aliphatic cyclic alkylene group containing at least one nitrogen atom and substituted with an alkyl group having 1-8 carbon atoms or a haloalkyl group having 1-8 carbon atoms in the ring; R71 and R73 represent —(CH2)rR76; R76 represents hydrogen atom, an alkyl group having 1-8 carbon atoms, a haloalkyl group having 1-8 carbon atoms, —NR77 R78, or a 3-8 membered saturated aliphatic cyclic alkyl group; Z represents C; A represents CH or N; R55, R56, R57, R58, R59, R62, R63, R65, R66, R67, R69, R70, R72, R74, R75, R77 and R78 each independently represents hydrogen atom, an alkyl group having 1-8 carbon atoms, or a haloalkyl group having 1-8 carbon atoms; m, q and r each independently represents an integer of 1-6; n and p each independently represents 0 or an integer of 1-6.
- 3. The method according to claim 1, wherein R51 represents an alkyl group having 1-8 carbon atoms, a haloalkyl group having 1-8 carbon atoms; R52 represents —C(═O)—; R53 represents —OR59, a 3-6 membered saturated aliphatic cyclic amino group optionally interrupted with nitrogen atom, oxygen atom or sulfur atom, a 3-6 membered saturated aliphatic cyclic amino group containing at least one nitrogen atom and substituted with an alkyl group having 1-6 carbon atoms or a haloalkyl group having 1-6 carbon atoms in the ring, or —NR60R61; R54 represents —(CH2)mNR62R63, —(CH2)nR64, —(CH2)pCH(NR65R66)COOR 67, —R68—COOR69, —CH(R70)OC(═O)OR71, or —CH(R72)OC(═O)R73; R60 and R61 each independently represents hydrogen atom, an alkyl group having 1-5 carbon atoms, a haloalkyl group having 1-5 carbon atoms, or —(CH2)qNR74R75; R64 represents a 3-6 membered saturated aliphatic cyclic amino group optionally interrupted with nitrogen atom, oxygen atom or sulfur atom, a 3-6 membered saturated aliphatic cyclic amino group containing at least one nitrogen atom and substituted with an alkyl group having 1-6 carbon atoms or a haloalkyl group having 1-6 carbon atoms in the ring, or a 3-6 membered unsaturated heterocyclic group; R68 represents a 3-6 membered saturated aliphatic cyclic alkylene group containing at least one nitrogen atom and substituted with an alkyl group having 1-6 carbon atoms or a haloalkyl group having 1-6 carbon atoms in the ring; R71 and R73 represent —(CH2)rR76; R76 represents hydrogen atom, an alkyl group having 1-5 carbon atoms, a haloalkyl group having 1-5 carbon atoms, —NR77R78, or a 3-6 membered saturated aliphatic cyclic alkyl group; Z represents C; A represents CH, or N; R55, R56, R57, R58, R59, R62, R63, R65, R66, R67, R69, R70, R72, R74, R75, R77 and R78 each independently represents hydrogen atom, an alkyl group having 1-5 carbon atoms, or a haloalkyl group having 1-5 carbon atoms; m, q and r each independently represents an integer of 1-4; n and p each independently represents 0 or an integer of 1-4.
- 4. The method according to claim 1, wherein R53 represents a 3-6 membered saturated aliphatic cyclic amino group containing at least one nitrogen atom and substituted with an alkyl group having 1-6 carbon atoms or a haloalkyl group having 1-6 carbon atoms in the ring, or —NR60R61 wherein at least one of R60 and R61 represents —(CH2)qNR74R75.
- 5. The method according to claim 1, wherein R54 represents —(CH2)mNR62R63, —(CH2)nR64, —(CH2)pCH(NR65R66)COOR67, —R68 —COOR69, —CH(R70)OC(═O)OR71, or —CH(R72)OC(═O)R73.
- 6. The method according to claim 1, wherein R53 represents a 3-7 membered saturated aliphatic cyclic amino group optionally interrupted with oxygen atom or sulfur atom.
- 7. The method according to claim 1, wherein R53 represents a morpholino group.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9-20925 |
Jan 1997 |
JP |
|
Parent Case Info
The following is a continuation of co-pending U.S. Ser. No. 08/991,411, filed Dec. 16, 1997.
US Referenced Citations (6)
Foreign Referenced Citations (12)
Number |
Date |
Country |
205 901 |
Jan 1984 |
DD |
27 33 156 A1 |
Feb 1978 |
DE |
0 138 720 A2 |
Apr 1985 |
EP |
0 253 310 A2 |
Jan 1988 |
EP |
0 253 310 A3 |
Aug 1990 |
EP |
0 475 206 A2 |
Mar 1992 |
EP |
0 475 206 A3 |
Aug 1992 |
EP |
0 588 299 A2 |
Mar 1994 |
EP |
0 588 299 A3 |
Jun 1994 |
EP |
0 685 470 A2 |
Jun 1995 |
EP |
0 685 470 A3 |
Jul 1996 |
EP |
0 807 628 A1 |
Nov 1997 |
EP |
Non-Patent Literature Citations (1)
Entry |
D.M. Pollock et al., “Angiotensin II Receptor Blockade Improves Renal Function in Rats with Reduced Renal Mass” J. Pharm. and Experimental Therapeutics 267(2):657-663 (1993). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
08/991411 |
Dec 1997 |
US |
Child |
09/166759 |
|
US |